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Abstract
Many common diseases have a complex genetic basis in which large numbers
of genetic variations combine with environmental factors to determine risk.
However, quantifying such polygenic effects has been challenging. In order to
address these difficulties we developed a global measure of the information con-
tent of an individual’s genome relative to a reference population, which may be
used to assess differences in global genome structure between cases and appro-
priate controls. Informally this measure, which we call relative genome informa-
tion (RGI), quantifies the relative “disorder” of an individual’s genome. In
order to test its ability to predict disease risk we used RGI to compare single-
nucleotide polymorphism genotypes from two independent samples of women
with early-onset breast cancer with three independent sets of controls. We
found that RGI was significantly elevated in both sets of breast cancer cases in
comparison with all three sets of controls, with disease risk rising sharply with
RGI. Furthermore, these differences are not due to associations with common
variants at a small number of disease-associated loci, but rather are due to the
combined associations of thousands of markers distributed throughout the
genome. Our results indicate that the information content of an individual’s
genome may be used to measure the risk of a complex disease, and suggest that
early-onset breast cancer has a strongly polygenic component.
Introduction
Accumulating evidence suggests that many common dis-
eases have a polygenic basis, in which large numbers of
genetic variations combine with environmental and life-
style factors to determine risk (Khoury et al. 2013). While
genome-wide association studies (GWAS), and more
recently exome and whole-genome sequencing projects,
have found hundreds of genetic variants associated with
disease, the ability to predict susceptibility from these
associations is generally low because the contribution of
individual variants to risk is often very modest. In the
case of breast cancer, published GWAS have identified
markers (single-nucleotide polymorphisms, or SNPs) in
more than 70 independent regions (loci), the majority
with odd ratios less than 1.1 (Bogdanova et al. 2013).
Collectively these loci explain, in the statistical but not
causative sense, approximately 15% of the familial relative
risk which, when combined with the approximately 21%
attributed to moderate- to high-penetrance variants (typi-
cally very rare mutations) in a dozen or so susceptibility
genes, leaves almost two-thirds of the familial basis of the
disease unaccounted for (Antoniou and Easton 2006;
Bogdanova et al. 2013). It is likely that additional genes
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that explain a proportion of this missing heritability will
be found using both whole-exome/genome and candidate
gene sequencing of familial and young-onset cases, where
the genetic component of risk is likely to be greatest
(Hopper and Carlin 1992; Manolio et al. 2009; Park et al.
2012; Ruark et al. 2013; Akbari et al. 2014). Nevertheless,
our current understanding of the genetic basis of breast
cancer is still far from complete.
While most studies to date have focussed on individual
genes or gene mutations and their contribution to disease,
there has been limited effort to quantify the cumulative
effect of variation across the whole genome on disease risk.
This is partly due to the historical lack of sufficient data to
appropriately quantify normal genomic variation within
control populations, and the absence of the statistical tech-
niques needed to analyze such large-scale variation. How-
ever, recent years have seen concerted effort to collect and
collate the large numbers of genomes (for example the UK
Department of Health’s 100K initiative http://www.ge-
nomicsengland.co.uk) and there is now a need to develop
the accompanying methodological tools to assess genomic
variation (Yang et al. 2011; Zhou et al. 2013).
In order to begin to address this issue we describe here
a measure of the extent to which a set of case genomes
differ from a set of control genomes in their global struc-
ture. Our method uses ideas from information theory to
provide a measure of the information content of an indi-
vidual’s genome with reference to a control population.
The procedure first uses the reference population to esti-
mate a probability measure on the space of all genomes,
and then uses the estimated probability measure to assess
how unusual an individual’s genome is with respect to
the reference population, as quantified by its self-informa-
tion (also known in information theory as “surprisal”)
(Cover and Thomas 1991). Formally, the resulting mea-
sure, which we refer to as the relative genome informa-
tion (RGI), is the amount of information, measured in
bits, required to specify the observed genome with respect
to the unique encoding that minimizes the expected num-
ber of bits required to specify the genome of an individ-
ual drawn at random from the reference population.
Informally, the RGI measures how unusual a genome is
with respect to the reference population or, since we con-
struct an information-theoretic measure closely related to
the Shannon entropy, how “disordered” it is. Thus, some-
one with a higher RGI has a more unusual genome, either
having less common alleles more often than expected, or
having some particularly rare alleles. By contrast a lower
RGI corresponds to having more common alleles more
often, and therefore a less surprising genome.
We hypothesized that global measures of genome varia-
tion, such as RGI, might quantify the polygenic basis of
complex diseases more completely than GWAS analyses
that seek to find statistically significant associations of
particular markers with disease. In order to test this
hypothesis we compared the RGI of two independent
samples of women with early-onset breast cancer geno-
typed for SNPs relative to three independent samples of
unaffected controls.
Methods
Data sets and quality control
SNP genotypes obtained from blood samples from the
following three independent studies were considered: (i)
The Prospective study of Outcomes in Sporadic versus
Hereditary breast cancer (POSH) cohort (Eccles et al.
2007). The POSH cohort consists of approximately 3000
women aged 40 years or younger at breast cancer diagno-
sis from which 574 cases were genotyped on the Illumina
(San Diego, CA, USA) 660-Quad SNP array. Genotyping
was conducted in two batches at the Mayo Clinic,
Rochester, MN (274 samples) and the Genome Institute
of Singapore, National University of Singapore (300 sam-
ples). A total of 536 samples that passed quality control
filters were considered in this study (Rafiq et al. 2013).
(ii) The Wellcome Trust Case Control Consortium
(WTCCC, http://www.wtccc.org.uk/). The WTCCC con-
sists of two independent sets of disease-free controls: 2699
individuals from the 1958 British Birth Cohort and 2501
individuals from the UK National Blood Service (NBS)
Collection. Genotyping of both sets was conducted using
the Illumina 1.2M chip. (iii) The Australian Breast Cancer
Family Study (ABCFS) (McCredie et al. 1998; Dite et al.
2003). Cases were a subset of 204 of women aged
40 years or younger at breast cancer diagnosis from the
ABCFS; controls were 287 unaffected women aged
40 years and older from the Australian Mammographic
Density Twins and Sisters Study (Odefrey et al. 2010).
Genotyping was conducted at the Australian Genome
Research Facility using the Illumina 610-Quad SNP array.
A summary of all data sets is given in Table 1.
Only autosomes were considered and SNPs were
excluded from each data set if they failed any of the fol-
lowing quality control filters: minor allele frequencies
<1%; genotyping call rate <99%; significant deviation
from Hardy–Weinberg equilibrium (P < 0.0001). All
quality control filters were implemented using the soft-
ware package PLINK (Purcell et al. 2007). In total,
approximately 475,000 SNPs were genotyped in all five
data sets. When comparing data sets and computing RGI
only these shared SNPs were considered.
Individuals with evidence of ethnic admixture were
excluded by performing multi-dimensional scaling (MDS)
analysis. Firstly, linkage disequilibrium (LD)-based pruning
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(r2 > 0.5) of genotypes was undertaken using PLINK to
generate a reduced set of approximately independent
SNPs. In total there were approximately 133,000 LD-
pruned SNPs common to all samples. The HapMap data
for the African, Asian, and Caucasian populations (Gibbs
et al. 2003) were then used to provide reference popula-
tion genotypes against which the genotype data of the
cases and controls were compared (Fig. 1A). We identi-
fied eight POSH and ten ABCFS samples that showed evi-
dence of mixed ethnicity that did not cluster well with
the HapMap Caucasian population reference sample, and
these were excluded from further analysis. Since they only
form a small subset of the total samples considered, the
conclusions of our analysis do not differ without removal
of these samples. However, we expect that, in general, sig-
nificant ethnic variation within either the case or control
populations would confound the results of our method.
Quantifying relative genome information
Let L denote a set of locations in the genome (loci), and let
Λ = {A, C, G, T} be the alphabet of possible alleles at each
locus l 2 L. Let Πl(k, l) denote the likelihood of finding
the unordered allele pair (k, l) 2 Λ 9 Λ at locus l 2 L in
Table 1. Overview of case and control data sets.
Data set Size Size after QC Gender Ethnicity Genotyping platform
ABCFS cases 204 201 Female Caucasian1 Illumina 610-Quad SNP array
POSH cases 574 536 Female Caucasian1 Illumina 660-Quad SNP array
ABCFS control 287 280 Female Caucasian1 Illumina 610-Quad SNP array
NBS control 2501 2501 Both Caucasian Illumina 1.2M chip
1958 control 2699 2699 Both Caucasian Illumina 1.2M chip
1post-QC.
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Figure 1. Breast cancer risk is associated with increased genome-wide disorder. (A) Multidimensional scaling plot of all samples and HapMap2
populations genotyped for ~133,000 SNPs. (B) Expected information per locus (EIL) for each of the different data sets. Median  95% confidence
intervals are shown. (C) Matrix of FDR adjusted P-values for comparisons of medians (two-sided Wilcoxon rank-sum test). (D) Q-Q plot of EIL in
cases versus controls. P-value from a two-sample Kolmogorov–Smirnov test is shown. (E) Estimated odds ratio as a function of EIL. (F) Median
number of loci required to account for the differences in EIL observed between cases and controls by percentile. 95% confidence intervals are
within the markers, so are not shown.
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the reference population and let Π be the product measure
of Πl over all l 2 L. Thus, K2L denotes the space of all pos-
sible genomes, and Π represents the probability measure
on K2L. Now let X 2 Λ2L be a genome with allele pair
Xt 2 Λ 9 Λ at locus l 2 L. We define the relative local
information (RLI) IlðXlÞ ¼  log2PlðXlÞ at each locus
l 2 L in the genome X and the RGI IðXÞ ¼PlL IlðXlÞ for
each genome X of interest. For the purposes of comparison
it is also convenient to normalize the RGI by n, the number
of loci genotyped, to give the expected information per
locus (EIL), EnðIlÞ ¼ 1n
P
lL IlðXlÞ. When comparing
sequences of the same length the EIL and RGI are equiva-
lent up to a normalizing factor. However, by normalizing
by the number of loci sampled, the EIL allows comparison
of relative information content of sequences of different
lengths (for instance, comparison of relative information
content of different chromosomes). The RLI is the natural
information-theoretic measure of the “surprisal” of observ-
ing allele pair Xl 2 Λ 9 Λ at locus l 2 L given the proba-
bility measure Πl (Cover and Thomas 1991). Similarly, the
RGI is the natural information-theoretic measure of the
“surprisal” of observing the genome X, given the probabil-
ity measure Π.
In practice Π is not known a priori and must be esti-
mated from an appropriate reference sample of similar
ethnic background to that of the cases. Here, we esti-
mated Π using the WTCCC 1958 birth cohort since it
was the largest reference sample available. In all calcula-
tions, Πl was estimated for each locus l 2 L using all
available genotypes in the reference population at that
locus. Once Π had been estimated, the RGI was calculated
for each genome in each of the remaining four (test)
samples (POSH cases, ABCFS cases, ABCFS controls, NBS
controls). The two additional independent sets of controls
(ABCFS and NBS) were included in order to assess the
robustness of the approximation of the background prob-
ability measure Π from the 1958 control cohort alone.
For each of the four test samples, missing genotype data
at each locus l 2 L were assigned the expected value of Πl
(i.e., the Shannon entropy PXl PlðXlÞ log2PlðXlÞ of
Πl). This method of imputation minimizes the influence
of missing data on the calculation of RGI. We also con-
ducted all calculations using only those loci for which
there were no missing readings in any of the data sets,
and results obtained with and without imputation did
not differ qualitatively. A brief worked example illustrat-
ing how Π was estimated, and the RLI and RGI were cal-
culated, is given in the Data S1. Estimation of RGI for N
case genomes takes O(n(m + N)) computational time,
where n is the number of loci and m is the number of
genomes in the control population, and can be conducted
on a desktop PC for moderate sample sizes (thousands of
samples and hundreds of thousands of genotyped loci).
Statistical analysis
All analysis was conducted in R and Matlab (Natick, MA,
USA) using custom written scripts. The association
between EIL and disease odds was estimated using a logis-
tic generalized additive model (Hastie et al. 2009). Tests
for significant differences between groups were assessed
using Wilcoxon rank-sum tests (two-sided tests were used
when testing the null hypothesis of no difference in EIL
between cases and controls against the alternative hypoth-
esis that EIL differs in cases and controls; one-sided tests
were used when testing the null hypothesis of no differ-
ence in EIL between cases and controls against the alter-
native hypothesis that EIL is raised in cases). All P-values
were false-discovery rate (FDR) adjusted using the Benja-
mini and Hochberg (1995) procedure.
Results
We did not observe any difference in EIL (RGI normal-
ized by the number of loci genotyped, EIL) between the
three different control sets (1958, NBS and ABCFS con-
trols) indicating that the background measure Π was reli-
ably estimated; similarly, no difference in EIL between
the POSH and ABCFS cases was observed (Fig. 1B and
C). However, EIL was significantly higher in both the
POSH and ABCFS cases than the three sets of reference
controls (FDR adjusted P < 0.01, two-sided Wilcoxon
rank-sum test) (Fig. 1B and C). Since significant differ-
ences within case and control sets were not observed, we
amalgamated samples to form one case set (consisting of
the ABCFS and POSH cases) and one control set (con-
sisting of the ABCFS, NBS and 1958 controls) for further
analysis. Comparison of the distribution of RGI in amal-
gamated case set and amalgamated control set revealed
significant differences in distribution structure
(P = 4.3 9 1010, two-sample Kolmogorov–Smirnov test)
with the case distribution having a substantially heavier
tail than the control distribution, indicating a greater
proportion of samples with higher EIL (Fig. 1D). To
investigate further we conducted regression using a logis-
tic generalized additive model (Hastie et al. 2009) in
order to estimate the relationship between disease odds
and EIL (Fig. 1E). Consistent with the heavy-tailed nat-
ure of the case distribution we observed a strong positive
association between odds ratio and EIL. In particular, the
odds ratio increased sharply for EIL above 1.75, with the
highest percentile EIL (above 1.183) having an odds ratio
greater than 12 by comparison with the lower 99%
(P < 1 9 1016, Fisher’s exact test). These results
indicate that EIL is significantly elevated in breast cancer
cases, with the highest percentiles EIL conferring a
substantially increased risk.
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In order to investigate the genetic basis for these obser-
vations we sought to assess whether the differences
observed were associated with particular genomic loci or
SNP annotations. We began by estimating the number of
loci required to account for observed differences at each
percentile using random resampling with replacement
(1 9 104 times) from the case genomes until the required
difference was achieved. Differences in median EIL between
cases and controls were found to be due to contributions
from an estimated 327 distinct loci (median, 95% confi-
dence intervals [306, 349]) (Fig. 1F). The expected number
of loci required to account for differences between cases
and controls sharply increased with percentile, with differ-
ences in the 99th percentile (which conferred the greatest
disease risk) requiring an estimated 4954 loci (median,
95% confidence intervals [4921, 5000]) (Fig. 1F). These
results indicate that observed differences in EIL are not due
to high-penetrance variations at a small number of disease-
associated loci, but rather are due to widespread variation
at thousands of genomic loci.
In order to investigate this further we assessed the EIL
on individual chromosomes. We found that EIL was con-
sistently elevated in the cases by comparison with the
controls on 19 of 22 chromosomes (Fig. 2A), and signifi-
cantly so on 12 of 22 chromosomes (FDR adjusted
P < 0.05, one-sided Wilcoxon rank-sum test), indicating
that differences in EIL are distributed throughout the
genome. We also observed notable variations in EIL by
SNP annotation, with the lowest EIL (and therefore the
least variation within the samples) occurring in the 50/30
untranslated and exonic regions, and the highest EIL (and
therefore the greatest variation within the samples) occur-
ring in the intergenic regions (Fig. 2B). This is consistent
with previous assessment of relative mutation rates and
suggests that 50/30 UTRs and exonic regions are subject to
stronger negative selection than intergenic regions, in
accordance with their phenotypic importance (Ward and
Kellis 2012a,b; Khurana et al. 2013). In all annotation cat-
egories, we again observed a significant increase in EIL in
the cases (FDR adjusted P < 0.05, one-sided Wilcoxon
rank-sum test) (Fig. 2B). These results indicate observed
differences in EIL are not localized to distinct regions of
the genome (either chromosomes or SNP annotations)
but rather are due to widespread variation distributed
throughout the genome.
Discussion
Genetic factors that contribute to breast cancer risk
range from rare highly penetrant functionally deleterious
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mutations in genes like BRCA1 and BRCA2 to genetic
variants that are relatively frequently observed and are
associated with small increases in risk (Mavaddat et al.
2010). However, we do not yet have a complete under-
standing of the genetic basis of breast cancer. Much of
the missing heritability may be either very rare highly
penetrant genes not currently known or, more likely,
hundreds to thousands of rare genetic variants with
small effect sizes. Current approaches to discovering
low-penetrance genetic susceptibility alleles using GWAS
rely on risk alleles being relatively common in the pop-
ulation. Even with case–control studies involving hun-
dreds of thousands of individuals, identifying all the
genes responsible for susceptibility is likely to prove dif-
ficult if important effects relate to the accumulation of
rare low-penetrance alleles. By comparing individual
genetic sequences with that expected from a control
population our approach assesses the cumulative effect
of low-penetrance alleles on disease risk. Our results
suggest that such cumulative effects are a significant
component of the missing heritability in breast cancer.
Prior to analysis all genotyping data were subjected to
stringent quality assurance and we observed no associa-
tion between sex, sequencing platform, time/place of
sequencing and EIL, indicating that poor data quality
or variation in genotype due to ethnicity or sex are
unlikely to explain our results (Figs. 1B, C, and 2C).
Rather, changes in EIL appear to quantify statistically
significant differences in allele frequencies between
breast cancer cases and controls.
Taken together our analysis indicates that early-onset
breast cancer has a strongly polygenic component, involv-
ing variation at thousands of markers distributed
throughout the genome. Thus, along with assessment of
known risk-associated variants, the information content
of an individual’s genome is likely to be a useful predictor
of breast cancer susceptibility. Further analysis of the rela-
tionship between global genome structure and disease risk
may reveal a similarly polygenic basis for a variety of
other complex diseases.
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